Arylthiazolylimidazoles as 5ht3 antagonists
CA 2016181 C · Owner: Pfizer Inc. · Inventors: Rizzi, James P.; Nagel, Arthur A.; Rosen, Terry J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Arylthiazolylimidazoles as 5HT3 antagonists useful in the treatment of nausea, anxiety, pain schizophrenia, and gastrointestinal disorders. Ar-HET-CH2-X wherein Ar is pyridyl, 3-indolyl; 8-quinolyl phenyl or, mono- or disubstituted phenyl wherein the substituent is each methyl, methoxy, fluoro, chloro or bromo; HET is thiazolyl; and X is imidazole or mono- or dimethylimidazole.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 7, 1990 and granted March 23, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 7, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 7, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.